Compare UiPath Inc (PATH) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Koninklijke Philips NV — how do they compare? UiPath Inc trades at $10.66 (market cap $6.24B), while Koninklijke Philips NV trades at $26.3 (market cap $25.89B). The key difference: Koninklijke Philips NV is far larger — about 4.1× UiPath Inc's market cap, and Koninklijke Philips NV pays a 3.81% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | PHG | |
|---|---|---|
Market Cap | $6.24B | $25.89B |
Sector | Technology | Health |
52-Week High | $19.29 | $32.91 |
52-Week Low | $9.38 | $25.02 |
Enterprise Value | $5.01B | $32.18B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $12.04, down 0.91% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while narrowing net losses signal a path toward sustained profitability. Recent news highlights strong annual recurring revenue growth to $1.9B and strategic AI automation developments through its Maestro platform.
The investment outlook is cautiously optimistic, supported by analyst consensus and improving margins, but risks include competitive pressures in AI automation and volatility in software spending. The stock presents a potential opportunity if execution on profitability continues, though near-term earnings misses warrant monitoring.
PHG trades at $26.58, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported net income of $895 million in 2025, a significant recovery from prior losses, with a net margin of 5.5%. Recent FDA clearances for medical devices and AI integrations highlight ongoing innovation. Cash flow from operations remains positive at $1.17 billion for 2025, though net cash flow declined to $403 million.
The outlook is mixed: analyst consensus is neutral with 59% hold ratings, reflecting caution despite recent profitability improvements. Key risks include high debt levels, with debt-to-asset ratio at 25.44% in 2025, and competitive pressures in health technology. Upside potential hinges on execution of AI-driven growth initiatives and margin expansion, as noted in Seeking Alpha analysis on 2026-05-20.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
